Monoclonal antobodies, benign breast disease, and breast cancer. A panel discussion

W. L. McGuire, R. L. Ceriani, J. Schlom, A. E. Frankel

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Hybridoma technology has now advanced to the point where hundreds of monoclonal antibodies have been produced and are reported to bind to normal and malignant cell surfaces or intracellular organelles. The original hope for tumor-specific antigens has not materialized, but certain antibodies with rather restricted ranges of binding activities have been indentified. This panel discusses the use of such monoclonal antibodies in diagnosis, prognosis, and treatment of human breast disease and breast cancer.

Original languageEnglish (US)
Pages (from-to)37-47
Number of pages11
JournalBreast Cancer Research and Treatment
Volume6
Issue number1
StatePublished - 1985

Fingerprint

Breast Diseases
Monoclonal Antibodies
Breast Neoplasms
Hybridomas
Neoplasm Antigens
Organelles
Technology
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Monoclonal antobodies, benign breast disease, and breast cancer. A panel discussion. / McGuire, W. L.; Ceriani, R. L.; Schlom, J.; Frankel, A. E.

In: Breast Cancer Research and Treatment, Vol. 6, No. 1, 1985, p. 37-47.

Research output: Contribution to journalArticle

@article{9d966059b4154734b5ef7fcafb5f3d35,
title = "Monoclonal antobodies, benign breast disease, and breast cancer. A panel discussion",
abstract = "Hybridoma technology has now advanced to the point where hundreds of monoclonal antibodies have been produced and are reported to bind to normal and malignant cell surfaces or intracellular organelles. The original hope for tumor-specific antigens has not materialized, but certain antibodies with rather restricted ranges of binding activities have been indentified. This panel discusses the use of such monoclonal antibodies in diagnosis, prognosis, and treatment of human breast disease and breast cancer.",
author = "McGuire, {W. L.} and Ceriani, {R. L.} and J. Schlom and Frankel, {A. E.}",
year = "1985",
language = "English (US)",
volume = "6",
pages = "37--47",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Monoclonal antobodies, benign breast disease, and breast cancer. A panel discussion

AU - McGuire, W. L.

AU - Ceriani, R. L.

AU - Schlom, J.

AU - Frankel, A. E.

PY - 1985

Y1 - 1985

N2 - Hybridoma technology has now advanced to the point where hundreds of monoclonal antibodies have been produced and are reported to bind to normal and malignant cell surfaces or intracellular organelles. The original hope for tumor-specific antigens has not materialized, but certain antibodies with rather restricted ranges of binding activities have been indentified. This panel discusses the use of such monoclonal antibodies in diagnosis, prognosis, and treatment of human breast disease and breast cancer.

AB - Hybridoma technology has now advanced to the point where hundreds of monoclonal antibodies have been produced and are reported to bind to normal and malignant cell surfaces or intracellular organelles. The original hope for tumor-specific antigens has not materialized, but certain antibodies with rather restricted ranges of binding activities have been indentified. This panel discusses the use of such monoclonal antibodies in diagnosis, prognosis, and treatment of human breast disease and breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0021891935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021891935&partnerID=8YFLogxK

M3 - Article

C2 - 3902124

AN - SCOPUS:0021891935

VL - 6

SP - 37

EP - 47

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -